RxDoctor Payments Data

Kavya Krishna, MD

Hematology & Oncology · Columbus, OHNPI 1194987537

Payments from drug & device makers

$10,312in general payments, 2019–2025

Across 10 payments — averaging $1031.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Genentech USA, Inc.$171
  • Dilon Technologies, Inc.$72
  • Gilead$26
  • Mckesson Specialty Care Distribution, LLC$16
  • Eisai Inc.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$22071%
  • Education$9229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$10,001
Genentech USA, Inc.2$171
Dilon Technologies, Inc.1$72
Gilead(2 entities)2$26
Mckesson Specialty Care Distribution, LLC1$16
Eisai Inc.1$15
Epizyme, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,312 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,340,322
Medicare patients
343
Services billed
105,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib45$628,549
IbrancePalbociclib20$307,235
ImbruvicaIbrutinib14$223,897
EliquisApixaban61$38,005
Abiraterone Acetate17$31,684
XareltoRivaroxaban17$12,311
Enoxaparin Sodium12$5,821
Anastrozole260$4,568
Exemestane31$2,393
Tamoxifen Citrate59$1,104
Prochlorperazine Maleate45$471
Oxycodone Hcl38$446
Gabapentin52$424
Ondansetron Hcl25$327
Dexamethasone14$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$10,001$345,24081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →